Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein kinase N kinases (PKN1, PKN2, and PKN3) are AGC-family serine/threonine protein kinases and effectors of the Rho family of small G proteins. These kinases play central roles in cell signaling pathways regulating actin cytoskeletal dynamics, cell migration, cell cycle progression, chromatin remodeling, cell adhesion, androgen receptor signaling, the immune response, and glucose metabolism. PKN1 and PKN2 are ubiquitously expressed, while PKN3 is expressed at lower levels in most tissues but higher in metastatic cancers. Activation of PKNs involves phosphorylation by PDK1 and interactions with Rho/Rac-family GTPases. Their dysregulation is implicated in various diseases, notably cancer, cardiovascular diseases, and some infections, marking them as promising yet understudied therapeutic targets. Isoform-specific targeting and understanding remain challenges for drug development and safety.
ATP-competitive inhibition (most kinase inhibitors), Induced degradation (e.g., PROTACs), Blockade of activation loop phosphorylation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein kinase N1 (PKN1).